Clinical Trial: A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL
Official Title: Pharmacokinetics of Imlunestrant in Participants With Hepatic Impairment
Brief Summary: The main purpose of this study is to measure how much of Imlunestrant (LY3484356) gets into the bloodstream and how long it takes the body to eliminate it in female participants with impaired liver function compared to female participants with normal liver function.
The side effects and tolerability of Imlunestrant will also be evaluated.
The study may last up to 46 days for each participant.
Detailed Summary:
Sponsor: Eli Lilly and Company
Current Primary Outcome: PK: Cmax of Imlunestrant
Original Primary Outcome: PK: Cmax of Imlunestrant
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Eli Lilly and Company
Dates:
Date Received: June 27, 2022
Date Started: July 05, 2022
Date Completion: February 23, 2024
Last Updated: January 12, 2024
Last Verified: January 01, 2024